32,334 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA acquired 32,334 shares of Zimmer Biomet Holdings, valued at approximately $3.38 million, during the first quarter.
• Currently, institutional investors hold 88.89% of Zimmer Biomet's shares, indicating strong institutional interest in the company.
• ZBH's recent quarterly earnings beat analysts' estimates with an EPS of $2.07, up from $2.01 in the previous year, and the company also announced a quarterly dividend of $0.24 per share.

Banque Transatlantique SA bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 32,334 shares of the medical equipment provider's stock, valued at approximately $3,382,000.

Other large investors have also recently bought and sold shares of the company. Garde Capital Inc. acquired a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $29,000. Menard Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. Washington Trust Advisors Inc. acquired a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $30,000. Finally, Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZBH. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Canaccord Genuity Group dropped their price target on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Royal Bank Of Canada boosted their price target on Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, UBS Group boosted their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $111.00.

Zimmer Biomet Trading Up 0.8%

NYSE:ZBH traded up $0.83 during trading hours on Friday, hitting $105.59. The company had a trading volume of 1,168,434 shares, compared to its average volume of 1,287,856. The company has a market cap of $20.92 billion, a P/E ratio of 25.69, a P/E/G ratio of 2.08 and a beta of 0.68. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a 50-day moving average of $98.42 and a 200 day moving average of $99.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is currently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.39% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.